Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$229.69 USD

229.69
406,015

-1.01 (-0.44%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

by Zacks Equity Research

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost

by Zacks Equity Research

Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS), owing to consistent improvement in its consumer-centric digital solutions and raised guidance.

NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

Nitish Marwah headshot

4 Momentum Picks Screened on Driehaus Strategy

by Nitish Marwah

COWN, LH, BBWI, and ARCB qualified as the momentum picks for the day, using the Driehaus strategy.

Stryker (SYK) to Boost Digital Capabilities With New Buyout

by Zacks Equity Research

Stryker (SYK) inks a deal with Vocera to enhance its digital healthcare offerings.

Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B

by Zacks Equity Research

Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada

by Zacks Equity Research

PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.

Best Value Stocks to Buy for January 6th

by Zacks Equity Research

M, LH, and SEKEY made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2022

    LabCorp (LH) Stock Moves -1.25%: What You Should Know

    by Zacks Equity Research

    LabCorp (LH) closed at $286.57 in the latest trading session, marking a -1.25% move from the prior day.

    STERIS (STE) Hits a New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Strong segmental performances are driving the top line for STERIS (STE).

    3 Reasons to Retain Integer Holdings (ITGR) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.

    Here's Why You Should Retain Cardinal Health (CAH) Stock Now

    by Zacks Equity Research

    Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.

    Here's Why You Should Hold on to Bruker (BRKR) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.

    Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

    by Zacks Equity Research

    Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

    Here's Why You Should Retain LHC Group (LHCG) Stock Now

    by Zacks Equity Research

    LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.

    Here's Why You Should Add Omnicell (OMCL) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.

    3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

    Here's Why You Should Hold on to NextGen (NXGN) Stock Now

    by Zacks Equity Research

    NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

    LabCorp (LH) Soars to 52-Week High, Time to Cash Out?

    by Zacks Equity Research

    LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.

    Quidel's (QDEL) Antigen Tests Successful in Omicron Detection

    by Zacks Equity Research

    The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.

    PacBio's (PACB) New Surveillance Kit Successful Against Omicron

    by Zacks Equity Research

    PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.